Management of hepatocellular carcinoma: an overview of major findings from meta-analyses
Metrics: PDF 1937 views | HTML 1877 views | ?
Xingshun Qi1,2,*, Yan Zhao2,3,*, Hongyu Li1,*, Xiaozhong Guo1, Guohong Han2
1Department of Gastroenterology and Meta-analysis Study Interest Group, General Hospital of Shenyang Military Area, Shenyang, 110840 China
2Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, 710032 China
3Department of Gastroenterology, First Affiliated Hospital of the Medical College, Xi’an Jiaotong University, Xi’an, 710000 China
*Co-first authors, these authors contributed equally to this work
Xingshun Qi, email: email@example.com
Xiaozhong Guo, email: firstname.lastname@example.org
Guohong Han, email: email@example.com
Keywords: hepatocellular carcinoma, treatment, management, meta-analysis, systematic review
Received: February 19, 2016 Accepted: April 11, 2016 Published: May 04, 2016
This paper aims to systematically review the major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma (HCC). A total of 153 relevant papers were searched via the PubMed, EMBASE, and Cochrane library databases. They were classified according to the mainstay treatment modalities (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial embolization or chemoembolization, sorafenib, and others). The primary outcome data, such as overall survival, diseases-free survival or recurrence-free survival, progression-free survival, and safety, were summarized. The recommendations and uncertainties regarding the treatment of HCC were also proposed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.